Literature DB >> 11465400

Limitations of stereotactic biopsy in the initial management of gliomas.

R J Jackson1, G N Fuller, D Abi-Said, F F Lang, Z L Gokaslan, W M Shi, D M Wildrick, R Sawaya.   

Abstract

Stereotactic biopsy is often performed for diagnostic purposes before treating patients whose imaging studies highly suggest glioma. Indications cited for biopsy include diagnosis and/or the "inoperability" of the tumor. This study questions the routine use of stereotactic biopsy in the initial management of gliomas. At The University of Texas M. D. Anderson Cancer Center, we retrospectively reviewed a consecutive series of 81 patients whose imaging studies suggested glioma and who underwent stereotactic biopsy followed by craniotomy/resection (within 60 days) between 1993 and 1998. All relevant clinical and imaging information was reviewed, including computerized volumetric analysis of the tumors based on pre- and postoperative MRI. Stereotactic biopsy was performed at institutions other than M. D. Anderson in 78 (96%) of 81 patients. The majority of tumors were located either in eloquent brain (36 of 81 = 44%) or near-eloquent brain (41 of 81 = 51%), and this frequently was the rationale cited for performing stereotactic biopsy. Gross total resection (>95%) was achieved in 46 (57%) of 81 patients, with a median extent of resection of 96% for this series. Diagnoses based on biopsy or resection in the same patient differed in 40 (49%) of 82 cases. This discrepancy was reduced to 30 (38%) of 80 cases when the biopsy slides were reviewed preoperatively by each of three neuropathologists at M. D. Anderson. Major neurologic complications occurred in 10 (12.3%) of 81 surgical patients and 3 (3.7%) of 81 patients undergoing biopsy. Surgical morbidity was probably higher in our series than it would be for glioma patients in general because our patients represent a highly selected subset of glioma patients whose tumors present a technical challenge to remove. Stereotactic biopsy is frequently inaccurate in providing a correct diagnosis and is associated with additional risk and cost. If stereotactic biopsy is performed, expert neuropathology consultation should be sought.

Entities:  

Mesh:

Year:  2001        PMID: 11465400      PMCID: PMC1920616          DOI: 10.1093/neuonc/3.3.193

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  115 in total

1.  Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies.

Authors:  Georg Widhalm; Georgi Minchev; Adelheid Woehrer; Matthias Preusser; Barbara Kiesel; Julia Furtner; Aygül Mert; Antonio Di Ieva; Boguslaw Tomanek; Daniela Prayer; Christine Marosi; Johannes A Hainfellner; Engelbert Knosp; Stefan Wolfsberger
Journal:  Neurosurg Rev       Date:  2012-03-10       Impact factor: 3.042

Review 2.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

3.  Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.

Authors:  Guido H Jajamovich; Chandni R Valiathan; Razvan Cristescu; Sangeetha Somayajula
Journal:  J Neurooncol       Date:  2016-07-08       Impact factor: 4.130

4.  Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas.

Authors:  C Majós; J Bruna; M Julià-Sapé; M Cos; A Camins; M Gil; J J Acebes; C Aguilera; C Arús
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-28       Impact factor: 3.825

Review 5.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

Review 6.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

7.  Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery.

Authors:  Timothy C Ryken; Bruce Frankel; Terrance Julien; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

8.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

9.  Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.

Authors:  Betty Y S Kim; Wen Jiang; Jason Beiko; Sujit S Prabhu; Franco DeMonte; Mark R Gilbert; Raymond Sawaya; Kenneth D Aldape; Daniel P Cahill; Ian E McCutcheon
Journal:  J Neurooncol       Date:  2014-04-29       Impact factor: 4.130

10.  Diagnostic challenges, management and outcomes of midline low-grade gliomas.

Authors:  Mueez Waqar; Shahid Hanif; Nitika Rathi; Kumar Das; Rasheed Zakaria; Andrew R Brodbelt; Carol Walker; Michael D Jenkinson
Journal:  J Neurooncol       Date:  2014-08-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.